Tags Archive Navigation
icon
-
Media ReleaseNew Phase III analysis demonstrates Novartis Beovu® showed improvement in best-corrected visual acuity in wet AMD patients with early persistent fluid
-
Media ReleaseResults from real-world data and post-hoc analysis of Novartis Beovu® pivotal trials presented at AAO 2020
-
Media ReleaseNovartis reports positive topline results from second Phase III trial of Beovu® in patients with diabetic macular edema
-
Media ReleaseNovartis Phase III Beovu® data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept
-
Media ReleaseNovartis reports one year results of Phase III MERLIN study evaluating Beovu® every four week dosing and provides update on Beovu clinical program
-
Media ReleaseNovartis receives EC Approval for Beovu®, a next-generation anti-VEGF treatment for wet AMD, a leading cause of blindness worldwide
-
Media ReleaseNovartis acquires Amblyotech, pursuing novel digital therapy for children and adult patients with “lazy eye”
-
Media ReleaseUS FDA approves updated Novartis Beovu® label, to include additional safety information
-
StoryNew Orbis Flying Eye Hospital helps fight blindness in China
-
StoryLessons from a blind chef
-
StoryGlaucoma silently steals sight
-
StoryCoping with eye disease and fading vision late in life